-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
news
newsToday, the Israeli company Novocure announced that its tumor treatment field (TTF) treatment device NovoTTF-200T combined with the PD-L1 drug Tecentriq and the angiogenesis inhibitor Avastin has obtained the FDA's breakthrough status in the first-line treatment of advanced liver cancer
.
This decision was based on the results of a Phase II clinical trial called HEPANOVA, which combined with Sorafenib to produce a 9.
5% response rate and a 76% disease control rate
Drug source analysis
Drug source analysisA common example of the human body being affected by electric fields is static electricity that makes your hair stand up
.
The discovery of TTF originated from in vitro cell experiments found that alternating electric fields affect the structure of cell division microtubules, thus accelerating tumor cell death
.
Similar to many local therapies such as ablation therapy and radiotherapy, TTF is a physical therapy
.
The energy of TTF is much lower than that of radiotherapy, but in theory it also faces the same selectivity problem as radiotherapy
.
The high lethality of advanced tumors makes current tumor drug development focus on efficacy
.
Prolonging life is important, but the quality of life cannot be ignored either
.
One of the most important developments is the development of new local therapies such as TTF
.
TTF is similar to chemotherapy in the second-line treatment of GBM, but it is much better tolerated, so it is marketed
.
